Recombinant Human Anti-Insulin precursor Soluble TCR (T17.1) (C-Cys) (CAT#: VS-0622-YF3940)
Human TCR (T17.1) recognizes Insulin precursor peptide (LALEGSL) in the context of . Soluble TCR is expressed with C-terminal Cys strategy (TRAV-TRAC partial-Cys, TRBV-TRBC partial-Cys). Depending the C-terminal Cys, two chains form heterodimer. Please note that the activity is not guaranteed.
Specific Inquiry
Specifications
- Host Species
- Human
- Target
- Insulin precursor
- Species Reactivity
- Human
- Epitope
- LALEGSL
- Clone
- T17.1
- Type
- Soluble TCR (C-Cys)
- Related Disease
- Others
- TCR Expression Strategy
- C-Cys strategy: the alpha and beta chain (without transmembrane and cytosolic region) can form heterodimer based on C-terminal Cys. The soluble TCR contains variable regions and partial constant regions.
Target
- Alternative Names
- Hypothetical Protein
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone T17.1"
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-0622-YF3940. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: ELISA, IF, Block, FuncS
Application: EM, ELISA, ICC, IHC-Fr, IHC-P, WB
For Research Use Only. Not For Clinical Use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
